Loading video...

Video Failed to Load

Go Home

Boosting exhausted T cells: Dr Daniel Utzschneider has identified how T cells can become exhausted from battling cancer, reducing the effectiveness of immunotherapy. He will use his CSL Centenary Fellowship to study these cells. Doherty Institute

20,278 views • 2 years ago •via X (Twitter)

4 Comments

Si Ming Man's profile picture
Si Ming Man2 years ago

@TheDohertyInst ⭐️ ⭐️

Jennifer Juno's profile picture
Jennifer Juno2 years ago

@TheDohertyInst Congrats Daniel!! @UtzschneiderD

GRAS Lab's profile picture
GRAS Lab2 years ago

@TheDohertyInst Congrats this is so great !!!!! 🎉🎉🎉🎉

Doherty Institute's profile picture
Doherty Institute2 years ago

👏

Related Videos

🚨ImmunityBio’s Anktiva: A New FDA-Approved Immunotherapy for certain bladder cancer. They are also developing treatments that may reduce the need for strong chemo, for blood cancer, lung cancer, brain cancer, and more. Broader approvals may take time. Someone call the President and fast-track this. Dr. Pat Soon-Shiong leads development beyond typical biotech efforts. Most cancer medicines, like chemotherapy, work by poisoning fast-growing cells to kill the cancer. This also hurts healthy cells, causing side effects like hair loss and weakness. Anktiva is different. It is an immunotherapy that wakes up your body’s own immune cells; natural killer cells and T cells to hunt and destroy cancer cells themselves. It acts like a booster shot for your immune system, using a protein called IL-15 to make these cells multiply and remember how to fight cancer long-term. ImmunityBio is different from most companies because of 3 big unique things: 1. They wake up 3 kinds of fighter cells at the same time: • NK cells (natural killers) • CD8 T cells (main attackers) • CD4 T cells (helpers) These three work together like a basketball team. This makes the body remember the cancer for a long time (maybe years). 2. They have a special cell line called NK-92. → It’s like buying frozen pizza instead of making dough from scratch every time. Doctors can just thaw it and give it to any patient. No need to take cells from the sick kid, customize them, and make them super weak with hospital chemo (that’s what normal CAR-T does). 3. Their medicine Anktiva gives a long, steady boost to the immune cells. Older drugs (like IL-2) gave a short, crazy boost that made people very sick. Anktiva is seems safer, so far. Exciting to follow the development. Interview: Chris Cuomo (NewsNation) — “Killing Cancer”

Black Panther Capital

40,249 views • 6 months ago

🚨 WHY ARE THERE OVER 400 PUBLISHED PAPERS ON IVERMECTIN AND CANCER? Because researchers discovered something unexpected. Ivermectin doesn't just target parasites. According to preclinical research, it appears to interact with cancer cells through multiple biological pathways. One of the most discussed? 📌 Cancer Stem Cells These are the cells believed to survive treatment, remain dormant for years, and potentially contribute to recurrence and spread. According to Dr. William Makis: 💊 Chemotherapy primarily targets rapidly dividing cancer cells. 💊 Ivermectin has been studied for its potential effects on cancer stem cells. That's why some researchers believe the combination deserves attention. But that's only part of the story. Researchers have also investigated ivermectin's potential ability to: ✅ Target cancer stem cells ✅ Influence tumor signaling pathways ✅ Alter cancer cell behavior ✅ Reverse chemotherapy resistance One of the most fascinating findings involves chemotherapy resistance. Over time, some cancer cells develop the ability to push chemotherapy drugs back out of the cell. Researchers have reported that ivermectin may interfere with these resistance mechanisms, potentially making cancer cells susceptible again. And then there's Fenbendazole and Mebendazole. While Ivermectin is being studied for one set of mechanisms, Fenbendazole and Mebendazole appear to work differently. Researchers have investigated their potential ability to: 📌 Block glucose transporters on cancer cells 📌 Reduce the cell's ability to use glucose as fuel 📌 Interfere with pathways associated with tumor growth Think about that. Different compounds. Different mechanisms. The same goal. That's why scientists continue publishing study after study. Not because these compounds are a fad. Because researchers keep uncovering new biological pathways worth investigating. And that's why the conversation around Ivermectin, Fenbendazole, and Mebendazole continues to grow. 💊 If you’re looking into these drugs, check out Ivermectin, Fenbendazole, and Mebendazole from RXMEDS.STORE. #Ivermectin #Fenbendazole #Mebendazole #CancerResearch #CancerStemCells #RepurposedDrugs #CancerBiology #RxMeds

RXMEDS.STORE

16,612 views • 2 months ago

A revolutionary approach to defeating cancer: Dr. Patrick Soon-Shiong unveils a game-changing strategy In a riveting discussion, Dr. Patrick Soon-Shiong, a pioneering surgeon and biotech innovator, laid out a bold, chess-like strategy to outsmart cancer—an enemy he describes as diabolically clever, hiding from the body’s immune defenses with sinister precision. Forget checkers; this is a war requiring the sophistication of Go, where every move counts. Here’s how Dr. Soon-Shiong’s cutting-edge approach is rewriting the rules of cancer treatment: Step 1: Smoke Out the Enemy Cancer isn’t just a clump of cells—it’s a cunning adversary with genomic tricks that let it cloak itself from killer T-cells. Dr. Soon-Shiong’s protocol starts by exposing the cancer’s hidden receptors. Instead of blasting the tumor with high-dose chemotherapy, he uses a low metronomic dose—a tiny amount that stresses the cancer, forcing it to reveal itself. “It’s like smoking it out,” he explains. The cancer, sensing danger, exposes its surface molecules, making it a target for the immune system. Step 2: Unleash the Body’s Elite Forces With the tumor exposed, Dr. Soon-Shiong deploys the body’s natural killer (NK) cells and T-cells, supercharged by a breakthrough molecule called BioShield. This activates NK cells, stimulates killer T-cells, and—crucially—creates memory T-cells that remember the cancer’s signature. “For the first time, we’re seeing bladder cancer patients in complete remission for nine years, still alive, without losing their bladders,” he revealed. This isn’t just treatment; it’s a long-term defense system. Step 3: Orchestrate a Multi-Front Assault Cancer thrives by suppressing the immune system, but Dr. Soon-Shiong’s approach is a battlefield symphony. He educates T-cells with a tailored vaccine, activates killer macrophages, and suppresses the suppressors—all simultaneously. Radiation? Only in tiny, precise doses (SBRT) to expose, not destroy. “High-dose radiation kills your NK and T-cells,” he warns. This is precision warfare, not carpet bombing. A Future Without Suffering Unlike traditional cancer treatments that leave patients nauseous, bald, and broken, Dr. Soon-Shiong’s protocol is outpatient-based, minimizing suffering. “We’ve treated hundreds of patients this way,” he shared. Even more revolutionary? He envisions treating patients before surgery, using the tumor itself as a vaccine to train the immune system. Imagine a world where cancer is stopped in its tracks without invasive procedures. The American Red Cross of Cancer Dr. Soon-Shiong’s vision goes beyond individual patients. By extracting and cryopreserving NK and T-cells from a single pint of blood, his team can grow billions of these immune warriors, ready to be deployed for anyone. “We could become the American Red Cross of cancer,” he declared, hinting at a future where these innovations could even shape global health policy. Why This Matters Cancer isn’t just a disease; it’s a biological mastermind that demands respect and strategy. Dr. Soon-Shiong’s approach—expose, activate, educate, and suppress—offers hope to millions facing a life-threatening diagnosis. His work proves that with the right tools, we can turn the body into its own greatest weapon. The Call to Action The FDA must recognize this multi-pronged war requires battlefield awareness, not outdated single-drug approvals. Patients deserve access to these life-saving protocols now.

Camus

94,391 views • 1 year ago

Dr. Patrick Soon-Shiong, a pioneering surgeon and scientist, reveals a shocking truth about chemotherapy, immunity, and why we’ve been fighting cancer the wrong way for decades. Here’s what’s simple—and profound: When you undergo chemotherapy, the first casualty is your red blood cells, leading to anemia (treated with Epogen). Next, it wipes out neutrophils, leaving you vulnerable to infection (treated with Neupogen). But the most devastating effect? It destroys your NK and T cells—your body’s elite cancer-fighting forces. Think about that: The very treatment meant to kill cancer also annihilates the only cells that can actually protect you from it. For 35 years, medicine has ignored this paradox. We replace red blood cells and neutrophils—but not the lymphocytes that matter most. The result? A weakened immune system, vulnerable to relapse and secondary cancers. Now, consider long COVID. The virus is cunning—it targets the same NK and T cells, crippling immunity. The parallel is undeniable: Weakening these cells leaves the body defenseless, whether from chemo or chronic infection. Dr. Soon-Shiong’s message is clear: "We’ve been treating cancer wrong." The future lies in restoring immune function, not just attacking tumors. The fight isn’t just against cancer or viruses—it’s for the immune system itself. And after 20 years of challenging the status quo, Dr. Soon-Shiong is leading that revolution. It’s time to rethink everything.

Camus

327,541 views • 1 year ago